Ongoing real world study reports high SVR rates for VIEKIRAX + EXVIERA in Gen 1
Cinnamon Girl said
Sep 14, 2015
New real world interim data from the independent AMBER study were presented for AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) with or without ribavirin in gen 1 chronic hep C infected patients. The primary endpoint of the study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR12). This study of Polish patients who reached post-treatent at week 12 (n=40 of 186 enrolled to date), demonstrated 98 percent (n=39/40) SVR12. These results further help to support the GT1 data shown in AbbVie's Phase 3 clinical trial development program. Interim data from the AMBER study were presented at the Viral Hepatitis Congress in Frankfurt, Germany.
New real world interim data from the independent AMBER study were presented for AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) with or without ribavirin in gen 1 chronic hep C infected patients. The primary endpoint of the study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR12). This study of Polish patients who reached post-treatent at week 12 (n=40 of 186 enrolled to date), demonstrated 98 percent (n=39/40) SVR12. These results further help to support the GT1 data shown in AbbVie's Phase 3 clinical trial development program. Interim data from the AMBER study were presented at the Viral Hepatitis Congress in Frankfurt, Germany.
Link to full details of press release...
http://www.prnewswire.co.uk/news-releases/ongoing-real-world-study-reports-high-sustained-viral-response-rates-with-viekirax-ombitasvirparitaprevirritonavir-tablets--exviera-dasabuvir-tablets-in-genotype-1-hepatitis-c-patients-526585651.html